|
FI94339C
(fi)
|
1989-07-21 |
1995-08-25 |
Warner Lambert Co |
Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
|
|
IN191236B
(https=)
|
1999-05-25 |
2003-10-11 |
Ranbaxy Lab Ltd |
|
|
US6646133B1
(en)
|
2000-10-17 |
2003-11-11 |
Egis Gyogyszergyar Rt. |
Process for the preparation of amorphous atorvastatin calcium
|
|
HU226640B1
(en)
*
|
1999-10-18 |
2009-05-28 |
Egis Gyogyszergyar Nyilvanosan |
Process for producing amorphous atorvastatin calcium salt
|
|
US7411075B1
(en)
|
2000-11-16 |
2008-08-12 |
Teva Pharmaceutical Industries Ltd. |
Polymorphic form of atorvastatin calcium
|
|
SI20425A
(sl)
*
|
1999-12-10 |
2001-06-30 |
LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. |
Priprava amorfnega atorvastatina
|
|
PL362981A1
(en)
|
2000-11-16 |
2004-11-02 |
Teva Pharmaceutical Industries Ltd. |
Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-beta,delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide
|
|
US7501450B2
(en)
*
|
2000-11-30 |
2009-03-10 |
Teva Pharaceutical Industries Ltd. |
Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
|
|
IL156055A0
(en)
|
2000-11-30 |
2003-12-23 |
Teva Pharma |
Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
|
|
CA2622477A1
(en)
|
2000-12-27 |
2002-07-04 |
Teva Pharmaceutical Industries Ltd. |
Crystalline forms of atorvastatin
|
|
WO2002057228A1
(en)
*
|
2001-01-17 |
2002-07-25 |
Biocon India Limited |
Atorvastatin calcium
|
|
WO2002057229A1
(en)
|
2001-01-19 |
2002-07-25 |
Biocon India Limited |
FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
|
|
SI20814A
(sl)
|
2001-01-23 |
2002-08-31 |
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. |
Priprava amorfnega atorvastatina
|
|
SI20848A
(sl)
*
|
2001-03-14 |
2002-10-31 |
Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. |
Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
|
|
IN190564B
(https=)
*
|
2001-04-11 |
2003-08-09 |
Cadila Heathcare Ltd |
|
|
BR0210666A
(pt)
*
|
2001-06-29 |
2004-10-05 |
Warner Lambert Co |
Formas cristalinas do sal de cálcio do ácido [r-(r*,r*)]-2-(4-fluorofenil)-beta, delta-dihidróxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)c arbonil]-1h-pirrol-1-heptanóico (2:1) (atorvastatina)
|
|
US7361772B2
(en)
|
2001-08-16 |
2008-04-22 |
Biocon Limited |
Process for the production of atorvastatin calcium
|
|
US7563911B2
(en)
|
2001-08-31 |
2009-07-21 |
Morepen Laboratories Ltd. |
Process for the preparation of amorphous atorvastin calcium salt (2:1)
|
|
UA77990C2
(en)
*
|
2001-12-12 |
2007-02-15 |
|
Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
|
|
CZ296967B6
(cs)
*
|
2002-02-01 |
2006-08-16 |
Zentiva, A.S. |
Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
|
|
HUP0500074A3
(en)
|
2002-03-18 |
2005-07-28 |
Biocon Ltd Bangalore |
Amorphous hmg-coa reductase inhibitors of desired particle size and process for producing them
|
|
RU2309141C2
(ru)
*
|
2002-03-18 |
2007-10-27 |
Байокон Лимитид |
АМОРФНЫЕ ИНГИБИТОРЫ ГМГ-КоА-РЕДУКТАЗЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ
|
|
ITMI20020907A1
(it)
*
|
2002-04-29 |
2003-10-29 |
Chemi Spa |
Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
|
|
WO2003099785A1
(en)
*
|
2002-05-28 |
2003-12-04 |
Cadila Healthcare Limited |
Process for the preparation of amorphous atorvastatin calcium
|
|
US7179942B2
(en)
|
2002-07-05 |
2007-02-20 |
Bicon Limited |
Halo-substituted active methylene compounds
|
|
WO2004022053A1
(en)
*
|
2002-09-03 |
2004-03-18 |
Morepen Laboratories Limited |
Atorvastatin calcium form vi or hydrates thereof
|
|
AU2004228607B2
(en)
*
|
2003-04-11 |
2011-01-27 |
Lek Pharmaceuticals D.D. |
Process for the preparation of amorphous calcium salt of atorvastatin
|
|
ES2323366T3
(es)
|
2003-04-22 |
2009-07-14 |
Biocon Limited |
Procedimiento novedoso para la reduccion estereoselectiva de beta-cetoesteres.
|
|
US7790197B2
(en)
*
|
2003-06-09 |
2010-09-07 |
Warner-Lambert Company Llc |
Pharmaceutical compositions of atorvastatin
|
|
US20040253305A1
(en)
*
|
2003-06-12 |
2004-12-16 |
Luner Paul E. |
Pharmaceutical compositions of atorvastatin
|
|
US20050271717A1
(en)
*
|
2003-06-12 |
2005-12-08 |
Alfred Berchielli |
Pharmaceutical compositions of atorvastatin
|
|
US7655692B2
(en)
*
|
2003-06-12 |
2010-02-02 |
Pfizer Inc. |
Process for forming amorphous atorvastatin
|
|
AU2003272080A1
(en)
|
2003-09-18 |
2005-04-06 |
Biocon Limited |
Novel process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate
|
|
CA2456430A1
(en)
*
|
2004-01-28 |
2005-07-28 |
Brantford Chemicals Inc. |
Improved process for the preparation of amorphous atorvastatin calcium
|
|
CZ298382B6
(cs)
*
|
2004-03-10 |
2007-09-12 |
Zentiva, A. S. |
Zpusob prípravy amorfní formy hemivápenaté soli atorvastatinu a její stabilizace
|
|
WO2005092852A1
(en)
|
2004-03-17 |
2005-10-06 |
Ranbaxy Laboratories Limited |
Process for the production of atorvastatin calcium in amorphous form
|
|
CA2649054A1
(en)
|
2004-05-05 |
2005-11-10 |
Pfizer Products Inc. |
Salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta., .delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
|
|
CA2573969C
(en)
*
|
2004-07-16 |
2014-02-04 |
Lek Pharmaceuticals D.D. |
Oxidative degradation products of atorvastatin calcium
|
|
US7645888B2
(en)
|
2004-08-27 |
2010-01-12 |
Biocon Limited |
Process for the production of amorphous atorvastatin calcium
|
|
EP1793815A4
(en)
*
|
2004-09-30 |
2010-12-29 |
Reddys Lab Ltd Dr |
AMORPHES ATORVASTATINCALCIUM
|
|
CN101039906A
(zh)
*
|
2004-10-18 |
2007-09-19 |
特瓦制药工业有限公司 |
通过将盐溶解于有机溶剂并除去该溶剂来制备无定形阿托伐他汀半钙的方法，所述有机溶剂为醇和酮和 /或酯的混合物
|
|
WO2006046109A1
(en)
|
2004-10-28 |
2006-05-04 |
Warner-Lambert Company Llc |
Process for forming amorphous atorvastatin
|
|
WO2006054308A2
(en)
|
2004-11-22 |
2006-05-26 |
Dexcel Pharma Technologies Ltd. |
Stable atorvastatin formulations
|
|
JP2008521878A
(ja)
*
|
2004-12-02 |
2008-06-26 |
ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー |
非晶質アトルバスタチンの医薬組成物及びその製造のための方法
|
|
US20080108664A1
(en)
|
2005-12-23 |
2008-05-08 |
Liu Belle B |
Solid-state form of AMG 706 and pharmaceutical compositions thereof
|
|
EP1810667A1
(en)
|
2006-01-20 |
2007-07-25 |
KRKA, tovarna zdravil, d.d., Novo mesto |
Pharmaceutical composition comprising amorphous atorvastatin
|
|
EP1877375A1
(en)
*
|
2006-03-01 |
2008-01-16 |
Teva Pharmaceutical Industries Ltd |
Process for preparing a crystalline form of atorvastatin hemi-calcium
|
|
WO2008053312A2
(en)
*
|
2006-11-02 |
2008-05-08 |
Cadila Pharmaceuticals Limited |
Process for preparing amorphous atorvastatin hemi calcium salt and its intermediate
|
|
US7834195B2
(en)
|
2007-01-24 |
2010-11-16 |
Apotex Pharmachem Inc. |
Atorvastatin calcium propylene glycol solvates
|
|
WO2009007856A2
(en)
*
|
2007-07-11 |
2009-01-15 |
Actavis Group Ptc Ehf |
Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium
|
|
US20090124817A1
(en)
*
|
2007-11-09 |
2009-05-14 |
The Industry & Academic Cooperation In Chungnam National University |
Process for Preparing Amorphous Atorvastatin Calcium Nanoparticles
|
|
EP2075246A1
(en)
|
2007-12-27 |
2009-07-01 |
M. J. Institute of Research |
A process for preparation of amorphous form of atorvastatin hemi-calcium salt
|
|
WO2010066846A2
(en)
*
|
2008-12-11 |
2010-06-17 |
Dsm Ip Assets B.V. |
Method for the isolation of atorvastatin
|
|
EP2373609B1
(en)
|
2008-12-19 |
2013-10-16 |
KRKA, D.D., Novo Mesto |
Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
|
|
EP2327682A1
(en)
|
2009-10-29 |
2011-06-01 |
KRKA, D.D., Novo Mesto |
Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
|
|
CZ201039A3
(cs)
|
2010-01-19 |
2011-07-27 |
Zentiva, K. S |
Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
|